Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP’s Project Team Calls for Audacious Gov’t Investment Targets for Drug Discovery Capabilities
April 30, 2021
- MHLW Revokes Approval for 12 Kobayashi Kako Products, Imposes Biz Improvement Order
April 30, 2021
- Bayer’s Heart Failure Med Now in Line for June Approval
April 30, 2021
- Large-Scale Vaccination Center to Open in Tokyo on May 24
April 28, 2021
- LDP Project Team Submits Proposal, Minister Vows to Subsidize Morning/Nighttime Vaccinations
April 28, 2021
- Rebuild Vaccine Development System as National Security: CEFP Members
April 27, 2021
- LDP Team Adopts Proposals to Push Japan-Made COVID-19 Vaccines, Urges Approval with Safety/Immunogenicity Studies
April 27, 2021
- Japan Eyes Different Supply Routes for Non-Pfizer COVID-19 Vaccines: Kono
April 26, 2021
- Don’t Take Vaccines If You Feel Ill: Safety Panels to Elderly
April 26, 2021
- Japan PM Mulls Legal Revision on Trial Requirement for Vaccines
April 26, 2021
- Olumiant Snags Japan Approval for COVID-19
April 23, 2021
- MSD’s Recarbrio, Rinvoq’s Psoriasis Use Clears PAFSC Review; June Approval Likely
April 22, 2021
- Major Modifications of CEA Scheme Difficult with Few Examples: Chuikyo
April 22, 2021
- Chuikyo Reps Warn Each Other over 2% Adjustment Rate in Drug Price Revisions
April 22, 2021
- MSD Developing 2-Dose Regimen for 9-Valent HPV Vaccine: Panel
April 22, 2021
- Olumiant Now in Line for Japan Nod for COVID-19 Pneumonia
April 22, 2021
- Vaccine Industry Group Calls for Govt’s Control Functions for Infectious Diseases
April 21, 2021
- Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
April 21, 2021
- FPMAJ Chief Calls for Uninterrupted Govt Support for Japan-Made Vaccines Even in Ordinary Times
April 20, 2021
- Over 50% of Itraconazole ADR Reporting Comes from Pharmacists in October-December: PMDA
April 20, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…